The unique characteristic of vaccination is that it not only reduces the incidence of disease in those immunized but also indirectly protects nonvaccinated susceptibles against infection (produces herd-immunity). The bulk of economic evaluations of vaccination programs continue to use models that cannot take into account the indirect effects produced by herd-immunity. Here, the authors illustrate the importance of incorporating herd-immunity externalities when assessing the cost-effectiveness of vaccination programs. To do this, they compare 2 methods of estimating the benefits of routine mass vaccination: one that includes herd-immunity (dynamic approach) and one that does not (static approach). Finally, they use the results to clarify a number of misconceptions that are common in the literature concerning herd immunity and dynamical effects produced by models.
Get full access to this article
View all access options for this article.
References
1.
1. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care cost benefit analysis and cost-effectiveness analysis from 1991 to 1996: an updated bibliography . Med Care. 1998;36: MS1–145 .
2.
2. Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics . Clin Ther. 1998;20: 1194–202 .
3.
3. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ . BMJ. 1996;313: 275–83 .
4.
4. Commonwealth of Australia. Guidelines for pharmaceutical industry and preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including economic analyses. Canberra, Australia: Department of Health and Community Services; 1995.
5.
5. Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics . Pharmacoeconomics. 1996;9: 535–59 .
6.
6. Lovatt B. The United Kingdom guidelines for the economic evaluation of medicines . Med Care. 1996;34(suppl): DS179–81 .
7.
7. Beutels P, Edmunds WJ, Antonanzas F, de Wit GA, Evans D, Feilden R, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis . Pharmacoeconomics. 2002;20: 1–7 .
8.
8. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective . Stat Med. 1999;18: 3263–82 .
9.
9. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press ; 1991.
10.
10. Fine PE. Herd immunity: history, theory, practice . Epidemiol Rev. 1993;15: 265–302 .
11.
11. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases . Nature. 1985;318: 323–9 .
12.
12. Nokes DJ, Anderson RM. The use of mathematical models in the epidemiological study of infectious diseases and in the design of mass immunization programmes . Epidemiol Infect. 1988;101: 1–20 .
13.
13. Rothberg M, Bennish ML, Kao JS, Wong JB. Do the benefits of varicella vaccination outweigh the long-term risks? A decision-analytic model for policymakers and pediatricians . Clin Infect Dis. 2002;34: 885–94 .
14.
14. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus . Epidemiol Infect. 2000;125: 651–9 .
15.
15. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. In press.
16.
16. Brisson M, Edmunds WJ. The cost-effectiveness of varicella zoster virus (VZV) vaccination in Canada . Vaccine. 2002;20: 1113–25 .
17.
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide . Med Decis Making. 1993;13: 322–38 .
18.
18. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom . Epidemiol Infect. 2001;127: 305–14 .
19.
19. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. In press.
20.
20. Atkinson WL, Orenstein WA, Krugman S. The resurgence of measles in the United States, 1989-1990 . Annu Rev Med. 1992;43: 451–63 .
21.
21. Cochi SL, Preblud SR, Orenstein WA. Perspectives on the relative resurgence of mumps in the United-States . Am J Dis Child. 1988;142: 499–507 .
22.
22. Chen RT, Weierbach R, Bisoff Z, et al. A “post-honeymoon period” measles outbreak in Muyinga sector, Burundi . Int J Epidemiol. 1994;23: 185–93 .
23.
23. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review . BMJ. 1999;319: 1462–7 .
24.
24. Bailey NJT. The Mathematical Theory of Infectious Diseases and Its Application. London: Griffin ; 1975.
25.
25. Schenzle D. An age-structured model of pre- and post-vaccination measles transmission . IMA J Math Appl Ned Biol. 1984;1: 169–91 .
